1-3 of 3
Hikari Araki
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

TAS0612, a Novel RSK, AKT, and S6K Inhibitor, Exhibits Antitumor Effects in Preclinical Tumor Models

Koji Ichikawa, Satoshi Ito, Emi Kato, Naomi Abe, Takumitsu Machida, Junya Iwasaki, Gotaro Tanaka, Hikari Araki, Kentaro Wakayama, Hideki Jona, Tetsuya Sugimoto, Kazutaka Miyadera, Shuichi Ohkubo
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2024) 23 (2): 174–186.
https://doi.org/10.1158/1535-7163.MCT-21-1037
Published: 01 February 2024
View article titled, TAS0612, a Novel RSK, AKT, and S6K Inhibitor, Exhibits Antitumor Effects in Preclinical Tumor Models
Open the PDF for TAS0612, a Novel RSK, AKT, and S6K Inhibitor, Exhibits Antitumor Effects in Preclinical Tumor Models in another window
Includes: Supplementary data
Journal Articles

TAS0728, A Covalent-binding, HER2-selective Kinase Inhibitor Shows Potent Antitumor Activity in Preclinical Models

Hiroki Irie, Kimihiro Ito, Yayoi Fujioka, Kei Oguchi, Akio Fujioka, Akihiro Hashimoto, Hirokazu Ohsawa, Kenji Tanaka, Kaoru Funabashi, Hikari Araki, Yuichi Kawai, Tadashi Shimamura, Renu Wadhwa, Shuichi Ohkubo, Kenichi Matsuo
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (4): 733–742.
https://doi.org/10.1158/1535-7163.MCT-18-1085
Published: 01 April 2019
View article titled, TAS0728, A Covalent-binding, HER2-selective Kinase Inhibitor Shows Potent Antitumor Activity in Preclinical Models
Open the PDF for TAS0728, A Covalent-binding, HER2-selective Kinase Inhibitor Shows Potent Antitumor Activity in Preclinical Models in another window
Includes: Supplementary data
Journal Articles

Abstract B179: TAS0728, a HER2-selective covalent inhibitor, demonstrates potent antitumor effect as a single agent and in combination with anti-HER2 antibodies in HER2-overexpressed tumor models

Hiroki Irie, Kei Oguchi, Kimihiro Ito, Yayoi Fujioka, Yuichi Kawai, Tadashi Shimamura, Hikari Araki, Akio Fujioka, Fumio Nakagawa, Rumi Kawabata, Hideki Nagase, Takeshi Sagara, Junji Uchida, Kenichi Matsuo, Teruhiro Utsugi, Yoshikazu Iwasawa
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1_Supplement): B179.
https://doi.org/10.1158/1535-7163.TARG-17-B179
Published: 01 January 2018
View article titled, Abstract B179: TAS0728, a HER2-selective covalent inhibitor, demonstrates potent antitumor effect as a single agent and in combination with anti-HER2 antibodies in HER2-overexpressed tumor models